These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26684641)

  • 1. Synergic development of pharmacokinetics and bioanalytical methods as support of pharmaceutical research.
    Marzo M; Ciccarelli R; Di Iorio P; Giuliani P; Caciagli F; Marzo A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):168-79. PubMed ID: 26684641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development steps of pharmacokinetics: a perspective on bioanalytical methods and bioequivalence.
    Marzo A
    Curr Clin Pharmacol; 2012 Nov; 7(4):328-32. PubMed ID: 22794161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical considerations into the new EMA guideline on bioequivalence.
    Marzo A; Fontana E
    Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management.
    Huang Y; Shi R; Gee W; Bonderud R
    Bioanalysis; 2012 Aug; 4(15):1919-31. PubMed ID: 22943622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action.
    Verbeeck RK; Musuamba FT
    J Pharm Pharm Sci; 2012; 15(3):376-88. PubMed ID: 23148877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New guidelines for the assessment of bioavailability and bioequivalence].
    Blume H; Schug B; Tautz J; Erb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):548-55. PubMed ID: 15887065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
    Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
    Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis.
    Savoie N; Booth BP; Bradley T; Garofolo F; Hughes NC; Hussain S; King SP; Lindsay M; Lowes S; Ormsby E; Phull R; Rocci ML; Vallano PT; Viau A; Zhu Z
    Bioanalysis; 2009 Apr; 1(1):19-30. PubMed ID: 21083184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence.
    García-Arieta A
    Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolites and bioequivalence: past and present.
    Jackson AJ; Robbie G; Marroum P
    Clin Pharmacokinet; 2004; 43(10):655-72. PubMed ID: 15244496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open questions on bioequivalence: some problems and some solutions.
    Marzo A
    Pharmacol Res; 1999 Oct; 40(4):357-68. PubMed ID: 10527649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
    Somayaji MR; Das D; Przekwas A
    Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.